Wells Fargo Upgrades Biogen to Overweight, Raises Price Target to $250

Benzinga Newsdesk www.benzinga.com Positive 82.5%

Neg 0% Neu 0% Pos 82.5%

Wells Fargo analyst Mohit Bansal upgrades Biogen (NASDAQ:BIIB) from Equal-Weight to Overweight and raises the price target from $200 to $250.